CRISPR-Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity.
Nicholas J KramerMichael S HaneyDavid W MorgensAna JovičićJulien CouthouisAmy LiJames A OuseyRosanna K MaGregor BieriC Kimberly TsuiYingxiao ShiNicholas T HertzMarc Tessier-LavigneJustin K IchidaMichael C BassikAaron D GitlerPublished in: Nature genetics (2018)
Hexanucleotide-repeat expansions in the C9ORF72 gene are the most common cause of amyotrophic lateral sclerosis and frontotemporal dementia (c9ALS/FTD). The nucleotide-repeat expansions are translated into dipeptide-repeat (DPR) proteins, which are aggregation prone and may contribute to neurodegeneration. We used the CRISPR-Cas9 system to perform genome-wide gene-knockout screens for suppressors and enhancers of C9ORF72 DPR toxicity in human cells. We validated hits by performing secondary CRISPR-Cas9 screens in primary mouse neurons. We uncovered potent modifiers of DPR toxicity whose gene products function in nucleocytoplasmic transport, the endoplasmic reticulum (ER), proteasome, RNA-processing pathways, and chromatin modification. One modifier, TMX2, modulated the ER-stress signature elicited by C9ORF72 DPRs in neurons and improved survival of human induced motor neurons from patients with C9ORF72 ALS. Together, our results demonstrate the promise of CRISPR-Cas9 screens in defining mechanisms of neurodegenerative diseases.
Keyphrases
- genome wide
- crispr cas
- amyotrophic lateral sclerosis
- genome editing
- dna methylation
- endoplasmic reticulum
- copy number
- spinal cord
- oxidative stress
- endothelial cells
- gene expression
- high throughput
- healthcare
- dna damage
- machine learning
- amino acid
- big data
- induced pluripotent stem cells
- genome wide identification
- affordable care act
- binding protein
- breast cancer cells
- single cell
- health insurance